[Platinum derivatives].
Sasaki
Yasutsuna
Y
Department of Clinical Oncology, Saitama Medical School.
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood* / Q000493:pharmacokinetics; D015415:Biomarkers / Q000097:blood; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics; D002851:Chromatography, High Pressure Liquid; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood* / Q000493:pharmacokinetics; D016903:Drug Monitoring / Q000379:methods*; D006801:Humans; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics; D000077150:Oxaliplatin; D013048:Specimen Handling; D013054:Spectrophotometry, Atomic
D000970:Antineoplastic Agents; D015415:Biomarkers; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; C053989:nedaplatin; D016190:Carboplatin; D002945:Cisplatin